This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Antipsychotic Agents and Sudden Cardiac Death — How Should We Manage the Risk?

List of authors.
  • Sebastian Schneeweiss, M.D., Sc.D.,
  • and Jerry Avorn, M.D.

Antipsychotic medications are commonly used across the entire age spectrum, both within and outside their labeled (and evidence-based) indications.1,2 Three atypical antipsychotic medications, olanzapine (Zyprexa, Eli Lilly), risperidone (Risperdal, Janssen), and quetiapine (Seroquel, AstraZeneca) are among the 10 top-selling drugs worldwide, with a combined sales volume of $14.5 billion in 2007.3 A thorough evaluation of risks is particularly important in the case of medications that are used so frequently and in such diverse patients, many of whom (e.g., children and the elderly) are particularly vulnerable. The effect of most antipsychotic medications on the electrophysiology of the heart has long . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Dr. Schneeweiss reports receiving an investigator-initiated research grant from Pfizer to study the safety of COX-2 inhibitors. No other potential conflict of interest relevant to this article was reported.

Author Affiliations

From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.